| Helping the human immune system to actively fight cancer |
immatics is an international leader in the development of peptide-based therapeutic cancer vaccines. The company's unique technology platform allows for the rapid identification of thousands of tumor-associated peptides directly from primary human tumor tissue.
immatics’ most advanced product IMA901 for the treatment of renal cell carcinoma (RCC) was brought from start of drug discovery to entry in man within less than 24 months. After successfully completing a European multi-centre phase 1 clinical trial with very encouraging results , the company has meanwhile also finished recruitment of metastatic RCC patients not responding to standard treatment into a phase II study with IMA901. In addition, immatics started in mid 2008 a phase I/II clinical proof-of-concept trial of its second vaccine product IMA910 in patients with advanced colorectal cancer. The company has several further products at earlier stages of preclinical development.
immatics was established in 2000 as a spin-out from the Institute of Immunology at the University of Tuebingen. Wellington was the lead investor in the company's first financing round in 2004 and invested again in 2007 in what was Germany’s largest biotech funding round for more than five years with a volume of EUR 40 million.
immatic’s target-specific therapeutic cancer vaccines can basically be developed in a majority of all cancer indications. Over 55 employees are currently working on the rapid transition of results from drug discovery and pre-clinical development to clinical programs.
Wellington’s Thomas Widmann, Erich Schlick and Rainer Strohmenger have helped immatics to establish a highly professional and efficient organisation focusing on rapid product development, differentiating immatics from many biotech companies that mainly focus on research.
